Welcome
Support Centre
11 October 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Multi-centre randomised controlled trial of symptomatic versus intensive bisphosphonate therapy for Paget's disease
ISRCTN ISRCTN12989577
ClinicalTrials.gov identifier
Public title Multi-centre randomised controlled trial of symptomatic versus intensive bisphosphonate therapy for Paget's disease
Scientific title
Acronym PRISM
Serial number at source ARC 13627
Study hypothesis Intensive bisphosphonate therapy is superior to symptomatic management in the prevention of long-term complications associated with Paget's disease of bone
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Paget's disease
Participants - inclusion criteria The trial will involve patients with Paget's disease over the age of 18 years with symptomatic or asymptomatic disease receiving care at participating hospitals throughout the UK.
Participants - exclusion criteria 1. Under 18 years of age
2. Unable to provide written consent
3. Judged by clinician to be too ill or frail to participate
4. Life expectancy of less than one year
Anticipated start date 01/12/2001
Anticipated end date 31/12/2010
Status of trial Ongoing
Patient information material
Target number of participants 1300
Interventions Patients will be randomised to either symptomatic treatment or intensive treatment with a bisphosphonate to maintain serum alkaline phosphatase within the normal range
Primary outcome measure(s) Fracture rate
Secondary outcome measure(s) 1. Progression of hearing loss
2. Self-reported health related quality of life
3. Requirement for joint replacement
Sources of funding 1. Arthritis Research Campaign (ARC)
2. Aventis & Procter & Gamble
3. National Association for Relief of Paget's Disease (NARPD)
Trial website http://www.abdn.ac.uk/hsru/hta/prism.shtml
Publications
Contact name Prof  SH  Ralston
  Address University of Edinburgh, Molecular Medicine Centre
Western General Hospital
Crewe Road South
  City/town Edinburgh
  Zip/Postcode EH4 2XU
  Country United Kingdom
  Tel +44 (0)131 651 1037 / 1035
  Fax +44 (0)131 651 1085
  Email stuart.ralston@ed.ac.uk
Sponsor University of Edinburgh and NHS Lothian (UK)
  Address Queen's Medical Research Institute
Room E1:06
47 Little France Crescent
  City/town Edinburgh
  Zip/Postcode EH16 4TJ
  Country United Kingdom
  Tel +44 (0)131 242 9262
  Fax +44 (0)131 242 9301
  Email marise.bucukoglu@ed.ac.uk
Date applied 05/02/2002
Last edited 22/01/2008
Date ISRCTN assigned 05/02/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central